Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Fondaparinux sodium
GSK576428 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Fondaparinux sodium | DRUG | - |
| GSK576428 | DRUG | - |
Inclusion criteria: * Patients aged \>=40 years undergoing the following abdominal (diaphragm to pelvic floor) surgery under general anesthesia lasting more than 45 minutes. * General or urologic surgery * Cancer surgery * Gynecologic surgery * Radical surgery for pelvic malignancy Exclusion crite...
GSK576428 is an investigational small molecule developed by GSK plc for the prevention of venous thromboembolism. It has been studied in a Phase 3 trial in Japanese patients undergoing abdominal surgery. GSK576428 is also known as fondaparinux sodium.
GSK576428 is being developed for venous thromboembolism, a condition involving blood clots in the veins. Its Phase 3 study evaluated the drug in Japanese patients undergoing abdominal surgery, a setting where clot prevention is a clinical concern.
GSK576428 is developed by GSK plc, which trades under the ticker GSK. The company sponsored the Phase 3 abdominal surgery study of the drug in Japanese patients.
GSK576428 has completed a Phase 3 clinical trial. It is an investigational agent and is not described as approved by the FDA. The completed Phase 3 study enrolled 127 patients in Japan.
GSK576428 has been studied in one Phase 3 trial, NCT00333021, titled Abdominal Surgery Study Of GSK576428 (Fondaparinux Sodium) In Japanese Patients. The trial enrolled 127 patients with venous thromboembolism in Japan and is completed.
Yes, GSK576428 is also known as fondaparinux sodium. The Phase 3 trial NCT00333021 lists the drug under both names in its title, studying it in Japanese patients undergoing abdominal surgery for venous thromboembolism.